Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Callahan

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of the American College of Cardiology|August 15, 2020
Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and BeyondMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
Stroke|October 11, 2008
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialHenrik Sillesen, Pierre Amarenco, Michael G Hennerici, et al.
Journal of the American College of Cardiology|March 21, 2020
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL TrialMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
Stroke|July 12, 2008
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudyLarry B Goldstein, Pierre Amarenco, Marian Lamonte, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 4, 2014
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trialBruce Ovbiagele, Larry B Goldstein, Pierre Amarenco, et al.
Stroke|January 30, 2010
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Henrik Sillesen, et al.
Stroke|May 23, 2009
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trialPierre Amarenco, Larry B Goldstein, Michael Messig, et al.
Stroke|October 27, 2007
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Michael Szarek, et al.
Stroke|September 12, 2009
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialLarry B Goldstein, Pierre Amarenco, Justin Zivin, et al.
Stroke|August 23, 2014
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trialPierre Amarenco, Alfred Callahan, Vito M Campese, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of the American College of Cardiology|August 15, 2020
Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and BeyondMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
Stroke|October 11, 2008
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialHenrik Sillesen, Pierre Amarenco, Michael G Hennerici, et al.
Journal of the American College of Cardiology|March 21, 2020
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL TrialMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
Stroke|July 12, 2008
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudyLarry B Goldstein, Pierre Amarenco, Marian Lamonte, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 4, 2014
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trialBruce Ovbiagele, Larry B Goldstein, Pierre Amarenco, et al.
Stroke|January 30, 2010
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Henrik Sillesen, et al.
Stroke|May 23, 2009
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trialPierre Amarenco, Larry B Goldstein, Michael Messig, et al.
Stroke|October 27, 2007
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Michael Szarek, et al.
Stroke|September 12, 2009
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialLarry B Goldstein, Pierre Amarenco, Justin Zivin, et al.
Stroke|August 23, 2014
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trialPierre Amarenco, Alfred Callahan, Vito M Campese, et al.
Pageof 2